The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab.
Hideaki Bando
Disclosure not yet available
Takayuki Yoshino
Disclosure not yet available
Eiji Shinozaki
Disclosure not yet available
Satoshi Yuki
Disclosure not yet available
Tomohiro Nishina
Disclosure not yet available
Shigenori Kadowaki
Disclosure not yet available
Kentaro Yamazaki
Disclosure not yet available
Katsuya Tsuchihara
Disclosure not yet available
Satoshi Fujii
Disclosure not yet available
Takeharu Yamanaka
Disclosure not yet available